Lantheus Holdings (LNTH) stock

Radiopharmaceutical products , market cap $6.6B

Radiopharmaceutical products

Worth $6.6B

Pre-market

$100.39

-0.22%

Close $100.61 -0.09%

As of 8:42 AM ET pre-market, delayed 15+ min · Live for Pro members

Quality Score

Below Average

In its industry

#52of 90

Pharma

Checks firing

3of 14

Choppy

From 52-week high

-10.1%

under its best in a year

LNTH's Quality Score was unchanged on Fri, Nov 6, at 0.

Follow LNTH's trial news. Pro members can get an alert when Lantheus Holdings files news, and see its trials, share raises, and its CEO's filings.

Get an alert when LNTH files news on its trialsSee it live, free until tomorrow morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

What LNTH filed on Nov 5

Down 0.4% on Nov 5, a down day for the market: the S&P 500 fell 4%, 86% of stocks fell, and pharma stocks a median 6%.

Its Nov 5 results: net income was $22.4M, from $27.8M a year before. It fell 0.4% on Nov 5.

Sources: Price history, Nov 5, 2026; Company release, Nov 5, 2026

The other side, the timeline, and its peers, for Pro members.

Key facts on LNTH

Key facts on LNTH
Latest filing	8-K, Nov 5 Reported its quarterly results

What's next

Mon Nov 16: 19th Annual Clinical Trials on…Industry event · date confirmed.

LNTH catalysts

Coming up

After its last 4 reports it closed +1.1% on average, higher 1 of 4 times.

8 past catalysts since 2019, with sizes and sources, for Pro members.

What's next for LNTH

Its trials

A trial underway: [18F]PI-2620 Phase 3 Histopathological StudyPhase 3 · Recruiting · 200 people · main data estimated Mar 2028 · NCT05641688

4 more trials, 39 filings, for Pro members.

Dilution on the horizon

No shelf registration or at-the-market program on file in the last three years.

For Pro members: the amounts, and the share count against a year ago.

Insiders

No open-market buys or sales by its officers or directors in their filings of the last year.

From Form 4: open-market buys and sales only.

Get an alert when Mary Heino buys or sells

For Pro members: every trade, and Mary Heino’s 12 filings and quotes.

Get an alert when LNTH files news on its trialsA free account. No card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 13 daysFDA decisionIn 13 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $500MDeramiocelFDA decision due (PDUFA)
In 13 daysFDA decisionIn 13 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $900MMolgramostimFDA decision due (PDUFA)
In 43 daysFDA decisionIn 43 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.3BLorundrostatFDA decision due (PDUFA)

14 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 151 dates, ranked →

Why LNTH scores 0

Below Averagefor quality, not price, 3 of 14 chart checks firingWhat the Quality Score means

+3Chart checks 3 of 14 firing right now, one point each
+2Long-term trend above a rising 200-⁠day average, near its 52-⁠week high, down over two years

Profit addsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
Growth subtractsSales and margins against a year earlier: up to +3 for fast growth and widening margins, down to -2 when both shrink.

No effect today: Run-up, Size, Dilution, Volatility, Cash flow, Persistence, and News.

What every line is worth, and the reason behind it, on LNTH and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 8:42 AM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

Alert me when LNTH's Quality Score turns up

A free account. No card.

How LNTH ranks in Pharma

LNTH is #52 of 90 by Quality Score.

How LNTH ranks in Pharma
Rank	Stock	Checks	Quality Score
1	ABBVAbbVie	8/14	24
2	LLYEli Lilly	5/14	18
3	CRONCronos	5/14	18
	KARDKardigan		Open for its score
	LQDALiquidia		Open for its score
	MANEVeradermics		Open for its score
52	LNTHLantheus	3/14	0

When does LNTH report earnings, and what happens after?

Expected to report Thu Feb 25, before the open (in 108 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What LNTH reported on Nov 5, 2026

The quarter

Sales of $389.9M, 2% more than a year ago; a profit of $0.33 a share, from $0.41.

The quarter that ended Sep 30, from the company's press release

The press release The filing on EDGAR

Where the sales came from

LNTH's results filing gives no sales by line in a table we read.

The outlook

No outlook figures read from this release.

The numbers

Market value: $6.6B; today
Sales: $1.6B; up 2.4% on the year

Sales grew 35% a year over 5 years, fiscal 2020 to 2025.

Its share count grew 4.8% a year over 5 years.

4 more figures, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on LNTH: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

+5.6%-0.4%-0.4%

May 7Aug 6Nov 5

Reported	When	Gap	Reaction	5 days
Nov 5, 2026Before open	Before open	+0.1%	-0.4%	not yet
Aug 6, 2026Before open	Before open	+0.0%	-0.4%	-0.8%
May 7, 2026Before open	Before open	+4.5%	+5.6%	+12.0%

LNTH closed higher after 1 of its last 4 reports.

All 4 reports, and LNTH's Quality Score going into each

LNTH sales and profit by year

Sales and profit by year

Sales grew in six of the last seven years, to $1.5B in 2025. It made a profit in six of the eight years.

LNTH has 3 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on LNTH, and all 14 on every stock.Get in free →

LNTH RSI on Nov 6: 54.8, above its 50-day and 200-day averages

Not scored

RSI 54.8, MACD above signal, above both averages. Not scored.13 readings

The deep dive on LNTH

What it does and how it makes money7 findingsIt kept 20 cents of each dollar of sales in fiscal 2025: $311M of operating profit on $1.54B of sales.Annual report, filed Feb 26, 2026"In the United States for PYLARIFY, we have patents listed in the FDA’s publication, ' Approved Drug Products with Therapeutic Equivalence Evaluations' (the 'Orange Book'), including composition of matter patents, the last of which expires in 2037." (10-K for fiscal 2025)SEC filing · Feb 26, 2026
Where it stands2 findingsFor Pro members2 findings on where LNTH stands: its cash, debt, and share count, for Pro members
What changed in its filings7 findings"On January 26, 2024, the Company was sued in the United States District Court for the District of Delaware (the 'District Court') by Advanced Accelerator Applications USA, Inc. and Advanced Accelerator Applications SA (collectively known as 'ADACAP' in the court proceedings) …" (10-Q for the quarter to Jun 30, 2026)SEC filing · Aug 6, 2026A new heading in its "Risk Factors" this year: "Potential generic competitors may seek to enter the market as a result of regulatory exclusivity expiration, including the expiry of NCE regulatory exclusivity for PYLARIFY in May 2026." (10-K for fiscal 2025; not in fiscal 2024's)SEC filing · Feb 26, 2026, against the one of Feb 26, 2025
Who holds and trades it2 findingsFor Pro members2 findings on who holds and trades LNTH, for Pro members

14 more findings on LNTH, each with its source, for Pro members.

LNTH's officers and directors

Officers and directors with a Form 4 in the last 12 months.

Mary Anne HeinoExecutive Chair and CEO · no trades on file
Robert J. Marshall Jr.CFO and Treasurer · no trades on file
Amanda Michelle MorganChief Commercial Officer · no trades on file
Daniel NiedzwieckiOfficer · no trades on file
Kimberly BrownChief Accounting Officer · no trades on file
Ludger DinkelborgOfficer · no trades on file
Gary J. PrudenDirector · no trades on file
Gerard BerDirector · no trades on file

7 more officers and directors file at LNTH.

See insider trades by person

Which ETFs hold LNTH?

In ETFs: LNTH is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Lantheus Holdings

Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.

1,193 employeesBedford, MAlantheus.com

What Lantheus Holdings says it competes with

“We believe that our key product characteristics, such as proven efficacy, reliability and safety, coupled with our core competencies, such as our efficient manufacturing processes, our established distribution network, our experienced field sales organization and our customer service focus, as well as our expanding product portfolio, are important factors that distinguish us from our competitors.”

From its annual report, SEC filing · Feb 26, 2026

Here is what Pro members see.

The same page for Pro members, on Microsoft
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on LNTH and every other stock.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

5 more filings explained, a plain line each
Real-⁠time prices, no delay
Every line of LNTH's score, with the points and the reason

See LNTH's 14 chart checks

See it live, free until tomorrow morning. No account. No card. Then keep going with a free account.

Straight AnswersStraight Answers

As of Nov 9, 2026: LNTH's Quality Score is 0 (Below Average), #52 of 90 in Pharma.

What does LNTH's Quality Score say?

LNTH scores 0 today, which Breakaway calls Below Average. It is #52 of 90 in Pharma by Quality Score, with 3 of 14 chart checks firing. Down 0.4% on Nov 5, a down day for the market: the S&P 500 fell 4%, 86% of stocks fell, and pharma stocks a median 6%. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is LNTH's Quality Score?

LNTH scores 0 today, which Breakaway calls Below Average (0 to 5). That is #52 of 90 in Pharma by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind LNTH's 0.

When does LNTH report earnings?

Expected to report Thu Feb 25, before the open, a date Breakaway expects from the company's usual timing; the company has not confirmed it. LNTH closed higher after 1 of its last 4 reports. Past behavior, not a forecast.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.